Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by Annex Advisory Services LLC

Annex Advisory Services LLC boosted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 18.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 87,145 shares of the company’s stock after buying an additional 13,710 shares during the quarter. Medpace makes up 0.9% of Annex Advisory Services LLC’s holdings, making the stock its 25th biggest position. Annex Advisory Services LLC owned about 0.28% of Medpace worth $28,952,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MEDP. Stone House Investment Management LLC acquired a new position in shares of Medpace during the 3rd quarter worth approximately $33,000. Ashton Thomas Securities LLC purchased a new stake in Medpace in the 3rd quarter worth $37,000. Capital Performance Advisors LLP acquired a new position in Medpace during the third quarter worth $46,000. True Wealth Design LLC lifted its holdings in Medpace by 16,800.0% during the third quarter. True Wealth Design LLC now owns 169 shares of the company’s stock valued at $56,000 after purchasing an additional 168 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its position in shares of Medpace by 95.7% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 225 shares of the company’s stock valued at $93,000 after purchasing an additional 110 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

MEDP has been the subject of several research analyst reports. TD Cowen reduced their price target on shares of Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. StockNews.com cut Medpace from a “buy” rating to a “hold” rating in a report on Friday, September 27th. UBS Group lowered Medpace from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $420.00 to $350.00 in a research note on Friday, September 27th. William Blair reissued an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Finally, Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and lowered their target price for the stock from $415.00 to $345.00 in a research note on Wednesday, September 25th. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Medpace presently has an average rating of “Hold” and a consensus target price of $380.56.

Medpace Stock Up 0.2 %

Shares of MEDP opened at $337.35 on Monday. Medpace Holdings, Inc. has a 52-week low of $284.32 and a 52-week high of $459.77. The stock has a fifty day simple moving average of $340.52 and a two-hundred day simple moving average of $356.98. The company has a market capitalization of $10.48 billion, a PE ratio of 29.54, a price-to-earnings-growth ratio of 1.80 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, October 21st. The company reported $3.01 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The company had revenue of $533.32 million for the quarter, compared to the consensus estimate of $540.99 million. During the same period in the previous year, the firm earned $2.22 earnings per share. Medpace’s quarterly revenue was up 8.3% compared to the same quarter last year. As a group, equities analysts anticipate that Medpace Holdings, Inc. will post 11.93 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.